Literature DB >> 17580238

Fabry disease model: a rational approach to the management of Fabry disease.

Christoph Wanner1.   

Abstract

Fabry disease (FD) is a truly progressive, multisystemic disorder. Clinically, the disease will present with 2 different faces throughout the lifetime of a patient: peripheral neurologic involvement predominates the symptoms in the first 3 decades of life (early symptoms), whereas major clinical events in the kidneys and heart or cerebrovascular system (late complications) largely determine the morbidity and mortality after 30 years of age. Before clinical manifestations occur in any organ system, there appears to be an insidious, subclinical progression of disease activities in various organ systems. Different stages of disease progression are associated with varying prognoses and potential responses to therapy, which provide a strong rationale for early intervention. Different stages may also be associated with various secondary pathologic events, which can provide indications for the use of a combination of interventions meant to control the primary pathology (lysosomal storage) as well as modifiable pathologies or correctable failures. A rational approach to FD and the therapy options available may help determine treatment choices and define therapeutic objectives as a function of optimal health outcomes, adequately reflecting the actual stage of disease progression, in individual patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17580238     DOI: 10.1016/s0149-2918(07)80115-9

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  6 in total

1.  Awareness of Fabry disease among rheumatologists--current status and perspectives.

Authors:  Rolando Cimaz; Severine Guillaume; Max J Hilz; Gerd Horneff; Bernhard Manger; J Carter Thorne; Anette Torvin Møller; Nico M Wulffraat; Johannes Roth
Journal:  Clin Rheumatol       Date:  2011-04       Impact factor: 2.980

Review 2.  Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Authors:  Roland M Schaefer; Anna Tylki-Szymańska; Max J Hilz
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

3.  Screening for Fabry Disease in Young Strokes in the Australian Stroke Clinical Registry (AuSCR).

Authors:  Alejandra Malavera; Dominique A Cadilhac; Vincent Thijs; Joyce Y Lim; Brenda Grabsch; Sibilah Breen; Stephen Jan; Craig S Anderson
Journal:  Front Neurol       Date:  2020-11-24       Impact factor: 4.003

4.  Removal of alpha-Gal epitopes from porcine aortic valve and pericardium using recombinant human alpha galactosidase A.

Authors:  Seongsik Park; Woong-Han Kim; Sun-Young Choi; Yong-Jin Kim
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

Review 5.  Fibrosis: a key feature of Fabry disease with potential therapeutic implications.

Authors:  Frank Weidemann; Maria D Sanchez-Niño; Juan Politei; João-Paulo Oliveira; Christoph Wanner; David G Warnock; Alberto Ortiz
Journal:  Orphanet J Rare Dis       Date:  2013-08-06       Impact factor: 4.123

6.  Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.

Authors:  F Weidemann; M Niemann; S Störk; F Breunig; M Beer; C Sommer; S Herrmann; G Ertl; C Wanner
Journal:  J Intern Med       Date:  2013-05-06       Impact factor: 8.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.